Drug intelligence / Profile preview

fecal microbiota transplantation (University of California, Irvine)

Development stage: Unknown
Lead developer: University of California, Irvine
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

This investigational fecal microbiota transplantation (FMT) therapy was developed by researchers at the University of California, Irvine, specifically for the treatment of refractory recurrent urinary tract infections (rUTI) in women. The therapy involves the administration of a single FMT via a retention enema, utilizing fecal microbiota sourced from healthy donors. The mechanism of action is based on the hypothesis that rUTIs are often seeded by uropathogens residing in a dysbiotic gut microbiome. By restoring gut species diversity and reducing the abundance of these uropathogens, the therapy aims to break the cycle of reinfection. A pilot study (FDA IND #17380) conducted in 2018 demonstrated safety and potential efficacy in reducing UTI frequency, with several participants no longer meeting the criteria for recurrent UTI post-treatment.

Other names: FMTfecal transplant

Beyond the preview

Go deeper on fecal microbiota transplantation (University of California, Irvine).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fecal microbiota transplantation (University of California, Irvine).

Explore the full profile